Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SOPHiA GENETICS ( (SOPH) ) has issued an announcement.
SOPHiA GENETICS SA has invited shareholders to its 2026 annual general meeting, scheduled for June 18, 2026, at the company’s offices in Rolle, Switzerland, with materials such as the formal invitation, meeting notice, and proxy cards distributed to investors. The May 8, 2025 communication underscores the company’s continued engagement with its global shareholder base as it reports strong 2025 operational progress and prepares for the next phase of growth.
In the run-up to this AGM, management highlighted that 2025 was a pivotal year, with reaccelerated revenue growth, record new customer additions, and over 391,000 analyses conducted on its platform, bringing the total to more than 2.3 million analyses. The company expanded its presence in the U.S., deepened partnerships with major cancer centers and AstraZeneca, launched new applications such as Enhanced Exome, MSK-IMPACT Flex, and Digital Twins, and rolled out a new generation of its SOPHiA DDM platform to handle nearly double the data volume while improving scalability and cost efficiency.
The most recent analyst rating on (SOPH) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on SOPHiA GENETICS stock, see the SOPH Stock Forecast page.
Spark’s Take on SOPH Stock
According to Spark, TipRanks’ AI Analyst, SOPH is a Neutral.
The score is primarily constrained by weak financial performance—deep losses, ongoing cash burn, and rising leverage/reduced equity. Offsetting factors include constructive technical momentum and a generally positive earnings call with reaffirmed growth guidance and a clearer path toward improving adjusted EBITDA, though near-term cash burn, FX, litigation, and back-half execution risk remain key headwinds.
To see Spark’s full report on SOPH stock, click here.
More about SOPHiA GENETICS
SOPHiA GENETICS SA is a Switzerland-based health-tech company focused on AI-driven genomics and data analytics for precision medicine. Its SOPHiA DDM platform supports decentralized genomic testing, liquid biopsy, and comprehensive genomic profiling, serving nearly 1,000 customers, including many leading cancer centers and institutions worldwide.
Average Trading Volume: 105,009
Technical Sentiment Signal: Buy
Current Market Cap: $387M
See more data about SOPH stock on TipRanks’ Stock Analysis page.